On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY 4 articles
July 28, 2008
- COMMENTARY／Industry Needs More Creative Thinking: NHI Pricing System Reform
July 21, 2008
- COMMENTARY／Will Fiscal Rehabilitation Policy Be Maintained?
July 7, 2008
- COMMENTARY／Daiichi Sankyo Surprises the World by Announcing Acquisition of Ranbaxy
June 30, 2008
- Pharmaceutical Partnerships in Japan for Regulatory and Commercial Success
June 30, 2008
- COMMENTARY 4 articles
June 9, 2008
- COMMENTARY／Shaking Pharmaceutical Administration System
May 19, 2008
- COMMENTARY／Personnel Strategy -New Graduates or Work-Ready MRs?
April 21, 2008
- COMMENTARY／Industry-Academia Cooperation Essential for Practical Use of iPS Cells
April 21, 2008
- COMMENTARY／Improvement of Drug Distribution Business Practices Goes into Crucial Stretch
April 14, 2008
- COMMENTARY／Mr Kodama Owes His Sweeping Victory to Members' Desire for Change: JPA
March 31, 2008
- COMMENTARY／Most Mainstay Products Avoid Deep Price Cuts in FY2008 NHI Price Revision
March 31, 2008
- Methodologic Issues in the Clinical Trial Study of Depression
March 24, 2008
- COMMENTARY／Preparations for New OTC Drug Marketing System Enter Final Stage
March 3, 2008
- COMMENTARY／Major Wholesalers vs Hansha Competition to Intensify on Growing Market for Generics
March 3, 2008
- COMMENTARY／Japan Needs to Create Attractive "Stadium for Drug Discovery" and Invite Top-Level Players
February 25, 2008
- COMMENTARY／Revision of Medical Fees May Increase Use of Drugs for Stroke, Mental Illnesses, Cancer
February 11, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry（2）
February 11, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry（1）
February 11, 2008
- COMMENTARY／Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes？
February 4, 2008
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…